Sorrento embarks on a multi-year cooperative research and
- Extensive multi-year agreement between Sorrento Therapeutics and the US Naval Medical Research Unit – No. 3 (NAMRU-3) headquartered in Sigonella, Italy, with laboratory detachments in Cairo, Egypt, Camp Lemonnier, Djibouti , and in Accra, Ghana.
- The scope includes infectious disease research and development, product validation, and disease surveillance to inform public health policy of host country partners and to improve the medical readiness of the U.S. military for the areas of responsibility NAMRU-3 (US European Command, US Central Command, United States Africa Command)
- The initial goal of the collaboration is to improve infectious disease preparedness through clinical diagnostic surveillance and validation activities for COVISTIX / COVITRACK diagnostic tests and COVIDROPS / COVI-AMG neutralizing antibody treatments for patients. COVID-19.
SAN DIEGO, June 22, 2021 (GLOBE NEWSWIRE) – Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced a comprehensive multi-year cooperative research and development (CRADA) agreement with NAMRU-3. Under the terms of the agreement, NAMRU-3 will conduct surveillance and clinical validation research, and Sorrento will provide technical expertise and access to its product portfolio to combat SARS-CoV-2 and emerging threats due to worrying variations.
The mission of NAMRU-3 is to ensure combatant readiness by detecting, deterring and responding to infectious disease threats through integration with partners in the areas of responsibility of the United States Africa Command (AFRICOM) , Central Command (CENTCOM) and European Command (EUCOM). The purpose of this collaboration is to conduct infectious disease research that guides the Department of Defense (DoD), informs the public health policy of host nation partners, and improves the medical readiness of the U.S. military in areas of responsibility of NAMRU-3. Through shared resources and logistical support, the overall objective of this research cooperation will be to conduct research on current, emerging and re-emerging infectious diseases, improve the health protection of the Force and provide essential data regarding countermeasures to mitigate the transmission of infectious diseases, including surveillance and product development.
The initial goal of the collaboration will be to improve infectious disease preparedness through clinical diagnostic surveillance and validation activities for COVISTIX / COVITRACK Diagnostics and outpatient treatment with COVIDROPS / COVI-AMG neutralizing antibodies. “We are excited about this opportunity to work with NAMRU-3 to quickly and efficiently assess and deploy our products in areas of the world where more effective solutions are desperately needed. – Dr. Henry Ji, President and CEO of Sorrento Therapeutics.
Since the start of this pandemic, Sorrento Therapeutics’ goal has been to leverage its proprietary G-MAB antibody library and develop best-in-class solutions to combat the SARS-CoV-2 virus and its variants. worrying. These include highly sensitive, simple and inexpensive diagnostics (COVISTIX, COVITRACK), strong neutralizing antibodies (COVI-AMG and COVIDROPS, which are the subject of outpatient clinical trials) and rescue therapies (Abivertinib and COVI-MSC, which are in clinical trials for hospitalized and critically ill patients) for COVID-19.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical-stage, antibody-focused biopharmaceutical company developing new therapies to treat cancer and COVID-19. Sorrento’s multimodal and multidimensional approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB ™ library”), immune therapies – clinical stage cells (“CAR-T”, “DAR-T ™”), antibody-drug conjugates (“ADC”) and clinical stage oncolytic virus (“Seprehvir ™”). Sorrento is also developing antiviral therapies and potential coronavirus vaccines, including COVIGUARD ™, COVI-AMG ™, COVISHIELD ™, Gene-MAb ™, COVI-MSC ™ and COVIDROPS ™; and diagnostic test solutions, including COVITRACK ™, COVISTIX ™ and COVITRACE ™.
Sorrento’s commitment to life-enhancing therapies is also demonstrated by our efforts to advance a first-class, non-opioid small molecule pain management (TRPV1 agonist), resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA ™), a new viscous gel formulation of a corticosteroid widely used for epidural injections to treat lumbosacral radicular pain, or sciatica, and to market ZTlido® (topical lidocaine system) 1.8% for the treatment of postherpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in patients with osteoarthritis. SEMDEXA is in a pivotal phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.
For more information visit www.sorrentotherapeutics.com
This press release and all statements made for and during any presentation or meeting contain forward-looking statements relating to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties. that could cause actual results to differ materially from those anticipated. Forward-looking statements include statements regarding the collaboration between NAMRU-3 and Sorrento to conduct infectious disease research and development, product validation and disease surveillance, and to improve medical preparedness; the potential of collaboration to improve infectious disease preparedness; the potential of clinical diagnostic surveillance and validation activities related to COVISTIX and COVITRACK diagnostic tests, and COVIDROPS and COVI-AMG antibody therapies, to help control SARS-CoV-2 and related variants of concern; the possibility of generating data to support countermeasures aimed at mitigating the transmission of current, emerging and re-emerging infectious diseases; the potential deployment of Sorrento’s products, including COVISTIX and COVITRACK diagnostic tests and COVIDROPS and COVI-AMG antibody products, worldwide; the diagnostic capabilities and potential therapeutic benefits of Sorrento’s product candidates, including the COVISTIX and COVITRACK diagnostic tests, the COVIDROPS and COVI-AMG antibody products, and the Abivertinib and COVI-MSC rescue therapies; and the likelihood that the development of Sorrento’s product candidates will result in best-in-class solutions to address SARS-CoV-2 and its variants of concern. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, without limitation: risks relating to Sorrento’s technologies and prospects, including, but not limited to: ” limit the risks associated with seeking regulatory approval for COVISTIX, COVITRACK, COVIDROPS, COVI-AMG, Abivertinib and COVI-MSC; clinical development risks, including risks related to the progress, timing, costs and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; the risks that the results of a clinical study will not meet all or part of the parameters of a clinical study and that the data generated from these studies will not support a regulatory submission or approval; the risks that the results of previous tests, studies and trials will not be reproduced in future studies and trials; risks associated with the manufacture and supply of pharmaceutical products; risks associated with using the expertise of its employees, subsidiaries, affiliates and partners to assist Sorrento in the execution of its therapeutic drug candidate strategies; risks associated with the global impact of COVID-19; and other risks which are described in Sorrento’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s annual report on Form 10-K for the fiscal year ended December 31, 2020, and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set out in those documents. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, and we assume no obligation to update any forward-looking statements contained in this press release, unless the law requires it.
Alexis Nahama, DVM (SVP Business Development)
E-mail: [email protected]
Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.
G-MAB ™, DAR-T ™, SOFUSA ™, COVIGUARD ™, COVI-AMG ™, COVISHIELD ™, Gene-MAb ™, COVIDROPS ™, COVI-MSC ™, COVITRACK ™, COVITRACE ™ and COVISTIX ™ are trademarks of Sorrento Therapeutics, Inc.
SEMDEXA ™ is a trademark of Semnur Pharmaceuticals, Inc.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.
All other trademarks are the property of their respective owners.
© 2021 Sorrento Therapeutics, Inc. All rights reserved.